Peyronie’s disease (PD) is a connective tissue disorder that affects the penis, specifically the tunica albuginea. It is characterized by fibrotic plaque formation that can lead to penile curvature, pain during erections, and erectile dysfunction over time. The condition affects an estimated 0.3% to 13.1% of men globally, though many cases likely remain unreported due to embarrassment or lack of awareness.
Clinically, PD is divided into two stages. The acute phase, also known as the active or unstable phase, involves pain during erections, early plaque development, and changing curvature. The chronic phase is more stable, with hardened plaques, reduced pain, and persistent deformity.
Current standard care mainly focuses on the chronic stage, often involving surgery or injectable therapies. There is still no widely approved, consistently effective oral treatment for early-stage disease progression. A recent clinical audit published in 2026 explored a combination therapy approach using off-label medications to address this gap.
The study, published in The Journal of Sexual Medicine (2026, Volume 23, Issue 6), evaluated a combination of phosphodiesterase type 5 inhibitors (PDE5 inhibitors) such as sildenafil or tadalafil and the selective estrogen receptor modulator tamoxifen in men with acute Peyronie’s disease.
Researchers previously identified that both PDE5 inhibitors and tamoxifen may have anti-fibrotic properties in laboratory and animal models. The rationale for this study was to evaluate whether combining these two drug classes could improve outcomes in real-world patients during the early inflammatory stage of PD.
This was a clinical audit involving 133 men diagnosed with acute Peyronie’s disease, defined as symptoms lasting less than 12 months. These patients received:
A comparison group included 26 patients from a separate hospital who received either no treatment or vitamin E as standard care.
Patients using other interventions such as vacuum erection devices or traction therapy were excluded to reduce confounding effects.
Both groups were similar in baseline characteristics, including age, symptom duration, penile curvature severity, and presence of pain prior to treatment.
One of the most important outcomes measured was change in penile curvature.
Patients receiving the combination therapy showed a statistically significant reduction in curvature after 3 months of treatment. This improvement remained significant even after adjusting for age and disease duration.
In contrast, the standard care group did not show meaningful improvement overall.
A breakdown of outcomes showed:
These results suggest that the combination therapy may help stabilize or even partially reverse early structural changes in Peyronie’s disease.
Penile pain during erection is a common symptom in the acute phase of PD. In this study, both groups experienced reductions in pain, but the magnitude of improvement differed significantly.
The reduction in pain was significantly greater in the combination therapy group, suggesting a stronger anti-inflammatory or disease-modifying effect rather than natural disease progression alone.
No adverse events or side effects were reported in either group during the 3-month treatment period. This suggests that the combination of tamoxifen and PDE5 inhibitors was well tolerated in this short-term observation.
However, it is important to note that absence of reported side effects in a small, non-randomized cohort does not guarantee long-term safety.
The findings support the hypothesis that combining tamoxifen and PDE5 inhibitors may target fibrotic processes in Peyronie’s disease more effectively than either approach alone.
Tamoxifen is thought to modulate fibrotic signaling pathways, while PDE5 inhibitors may improve vascular function and potentially influence tissue remodeling. Together, they may reduce inflammation and slow progression of fibrotic plaque formation during the acute phase.
The study also reinforces an important clinical concept: timing matters. Previous research has shown that tamoxifen appears more effective in early-stage PD and less beneficial once the disease becomes chronic and stable.
Earlier studies have examined combinations of tamoxifen with other agents such as L-carnitine, tadalafil, or vacuum erection devices. Those studies suggested potential benefits, but results were inconsistent due to differing protocols and combination therapies.
This 2026 audit is notable because it evaluates tamoxifen combined specifically with PDE5 inhibitors without additional mechanical devices, providing a more focused assessment of drug synergy.
Despite promising results, several limitations must be considered:
Because of these limitations, the results should be interpreted as preliminary clinical evidence rather than definitive proof of efficacy.
The authors emphasize the need for larger, randomized controlled trials to validate these findings. Future studies should include:
Such studies would help determine whether this combination therapy could become a standard non-surgical option for early Peyronie’s disease.
This 2026 clinical audit suggests that combining PDE5 inhibitors with tamoxifen may offer meaningful benefits for men in the acute phase of Peyronie’s disease. The observed improvements in penile curvature and pain reduction are encouraging, particularly given the lack of established oral treatments for early-stage disease.
However, due to methodological limitations, these findings should be viewed as early evidence. More rigorous clinical trials are necessary before this combination can be recommended as standard treatment.
Shah M, Megson M, et al. Evaluation of a combination of off-label PDE5 inhibitor and tamoxifen in acute Peyronie’s disease. The Journal of Sexual Medicine, 2026, 23(6), qdag120.
DOI:
This article is for informational and educational purposes only. It is based on a published clinical audit and does not constitute medical advice, diagnosis, or treatment recommendations. The therapies described, including off-label use of medications, should only be considered under the supervision of a qualified healthcare professional. Readers should not start or modify any medication regimen based on this content without consulting a licensed medical provider.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.